BMSSC
FATE icon

B. Metzler seel. Sohn & Co’s Fate Therapeutics FATE Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,590
Closed -$147K – 736
2022
Q4 		$147K Hold
14,590
– – ﹤0.01% 712
2022
Q3 		$327K Buy
14,590
+998
+7% +$28.8K 0.01% 612
2022
Q2 		$337K Hold
13,592
– – 0.01% 625
2022
Q1 		$527K Buy
+13,592
New +$526K 0.01% 585

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

B. Metzler seel. Sohn & Co's FATE Position: Q1 2023 in Review

B. Metzler seel. Sohn & Co sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 14,590 shares — an estimated $147K sold.

B. Metzler seel. Sohn & Co first reported a position in FATE in Q1 2022 and held it in 4 quarters. The position peaked at $527K in Q1 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • B. Metzler seel. Sohn & Co reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 14,590 Fate Therapeutics shares in Q1 2023, an estimated $147K.
  • B. Metzler seel. Sohn & Co first reported a position in Fate Therapeutics in Q1 2022 and held it in 4 quarters.
  • B. Metzler seel. Sohn & Co's Fate Therapeutics position peaked at $527K in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2023, filed 10 May 2023.